Cargando…

Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells

BACKGROUND: Excessive maturation of hematopoietic cells leads to a reduction of long-term proliferative capability during cord blood (CB) expansion. In this study, we report the effects of anit-CD52 (Alemtuzumab, Campath) on both short- and long-term ex vivo expansion of CB hematopoietic stem cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Che K, Sun, Li, Feng, Qi, Law, Ping, Chua, Wei T, Lim, Shy N, Hwang, William YK
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582233/ https://www.ncbi.nlm.nih.gov/pubmed/18947412 http://dx.doi.org/10.1186/1756-8722-1-19

Ejemplares similares

Clinical pharmacology of alemtuzumab, an anti‐CD52 immunomodulator, in multiple sclerosis
por: Li, Z., et al.
Publicado: (2018)

Ex Vivo Expansion of CD34(+)CD90(+)CD49f(+) Hematopoietic Stem and Progenitor Cells from Non‐Enriched Umbilical Cord Blood with Azole Compounds
por: Bari, Sudipto, et al.
Publicado: (2018)

CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment
por: Hotta, Ryuichi, et al.
Publicado: (2016)

CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation
por: Shafiei-Jahani, Pedram, et al.
Publicado: (2021)

Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52(+) T-cell malignancies
por: Miljkovic, Milos D., et al.
Publicado: (2022)

Proteomic Profiling of Ex Vivo Expanded CD34-Positive Haematopoetic Cells Derived from Umbilical Cord Blood
por: Falkenberg, Heiner, et al.
Publicado: (2013)

An effective ex-vivo approach for inducing endothelial progenitor cells from umbilical cord blood CD34(+) cells
por: Qin, Meng, et al.
Publicado: (2017)

Low-dose insulin-like growth factor binding proteins 1 and 2 and angiopoietin-like protein 3 coordinately stimulate ex vivo expansion of human umbilical cord blood hematopoietic stem cells as assayed in NOD/SCID gamma null mice
por: Fan, Xiubo, et al.
Publicado: (2014)

Intercellular cytosolic transfer correlates with mesenchymal stromal cell rescue of umbilical cord blood cell viability during ex vivo expansion
por: Chu, Pat P. Y., et al.
Publicado: (2012)

Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells from Umbilical Cord Blood
por: Sotnezova, E.V., et al.
Publicado: (2016)

Differential ability of MSCs isolated from placenta and cord as feeders for supporting ex vivo expansion of umbilical cord blood derived CD34(+) cells
por: Kadekar, Darshana, et al.
Publicado: (2015)

Ex vivo generation of umbilical cord blood T regulatory cells expressing the homing markers CD62L and cutaneous lymphocyte antigen
por: Kellner, Joshua N., et al.
Publicado: (2018)

A novel monoclonal antibody of human stem cell factor inhibits umbilical cord blood stem cell ex vivo expansion
por: Fan, Jie, et al.
Publicado: (2012)

Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis
por: Rao, Sambasiva P., et al.
Publicado: (2012)

CH02 peptide promotes ex vivo expansion of umbilical cord blood-derived CD34 (+) hematopoietic stem/progenitor cells : CH02 peptide promotes CD34 (+) UCB-HSPC ex vivo expansion
por: Yang, Yiqi, et al.
Publicado: (2023)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients
por: Sylvan, S Eketorp, et al.
Publicado: (2014)

Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis
por: Nosher, Sadia, et al.
Publicado: (2021)

Potent ex vivo expanded, human CD34+ cord blood-derived natural killer cells for cancer immunotherapy
por: Zhang, Xiaokui, et al.
Publicado: (2015)

Evaluation of Expansion and Maintenance of Umbilical Cord Blood CD34(+) Cells in The Co-Culture with Umbilical Cord Blood-Derived Mesenchymal Stem Cells in The Presence of Microcarrier Beads
por: Naseri Mobaraki, Sepideh, et al.
Publicado: (2023)

Wnt1 Accelerates an Ex Vivo Expansion of Human Cord Blood CD34(+)CD38(−) Cells
por: Chotinantakul, Kamonnaree, et al.
Publicado: (2013)

CD94 Ex Vivo Cultures in a Bone Marrow Transplantation Setting
por: Abrams, Kraig, et al.
Publicado: (2020)

Engineering an anti-CD52 antibody for enhanced deamidation stability
por: Qiu, Huawei, et al.
Publicado: (2019)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021)

Ex Vivo Expansion of Human Limbal Epithelial Cells Using Human Placenta-Derived and Umbilical Cord-Derived Mesenchymal Stem Cells
por: Nam, Sang Min, et al.
Publicado: (2017)

Optimization of ex vivo hematopoietic stem cell expansion in intermittent dynamic cultures
por: Choi, Yong-Soo, et al.
Publicado: (2010)

CD34(+) stem cells from umbilical cord blood
por: Pafumi, Carlo, et al.
Publicado: (2011)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab
por: Ali, Liaqat, et al.
Publicado: (2020)

Failure of alemtuzumab therapy in three patients with MOG antibody associated disease
por: Seneviratne, Sinali O., et al.
Publicado: (2022)

Depletion of CD52‐positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune‐tolerance promoting CD8 T‐cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis
por: von Kutzleben, Stephanie, et al.
Publicado: (2017)

Recombinant TAT-BMI-1 fusion protein induces ex vivo expansion of human umbilical cord blood-derived hematopoietic stem cells
por: Codispoti, Bruna, et al.
Publicado: (2017)

Mesenchymal Stromal Cells from Perinatal Tissues as an Alternative for Ex Vivo Expansion of Hematopoietic Progenitor and Stem Cells from Umbilical Cord Blood
por: Bonilla, Ximena, et al.
Publicado: (2023)

Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma
por: Kinder, Michelle, et al.
Publicado: (2021)

Enhancement of wound closure in diabetic mice by ex vivo expanded cord blood CD34(+) cells
por: Chotinantakul, Kamonnaree, et al.
Publicado: (2013)

Large-scale ex vivo generation of human neutrophils from cord blood CD34(+) cells
por: Jie, Zhenwang, et al.
Publicado: (2017)

Pregnancy and umbilical cord pathology: structural and functional parameters of the umbilical cord
por: Dubetskyi, Bohdan Ihorovych, et al.
Publicado: (2023)

Alemtuzumab in the up-front setting
por: Kaufman, Matthew, et al.
Publicado: (2008)

Alemtuzumab in chronic lymphocytic leukemia
por: Fraser, G., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ljkv6sndpce8jr65qh66flcqme